Assess heart and stroke events after starting triple COPD inhalers
Part of Lungs & breathing clinical trials.
This study looks at how often heart problems or stroke happen in people with COPD after they start a specific “triple therapy” inhaler. It may help doctors understand whether these inhalers change cardiovascular (heart) or cerebrovascular (stroke) risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a COPD diagnosis.
- You are age 40 or older.
- You have at least 12 months of past medical information available before starting treatment.
- You are starting a specific triple-inhaler medicine (BDP/FF/GB) for the first time using either a dry-powder inhaler or a pMDI (metered-dose inhaler).
- You have not used any triple-therapy inhaler (single or multiple inhalers) in the last 90 days.
- You were not hospitalized for heart-related causes in the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination inhaler (fluticasone, formoterol, and glycopyrronium) for people with COPD. It aims to see if this triple therapy can improve breathing and quality of life compared to current treatments.
This study looks at how well a triple-combination inhaler called Breztri/Trixeo works for people with moderate to severe COPD. If you have been prescribed this inhaler but haven't started it yet, and you are between 30 and 80 years old, you may be able to join.
This study tests a triple-combination inhaler (budesonide, glycopyrronium, formoterol) against a placebo inhaler to see how it affects your heart and lungs if you have COPD and over-inflated lungs.
This study tests a triple-combination inhaler (budesonide, glycopyrronium, and formoterol) to see if it can help protect the heart and lungs in people with COPD who also have heart problems or high risk for them.
This study looks at whether a breathing test called oscillometry can help guide treatment when switching from two inhaled medicines to triple therapy (including a steroid) for people with COPD who often have flare-ups.
This study looks at how a simple breath test (measuring nitric oxide in the air you breathe out) might help predict when COPD symptoms flare up. If you take triple inhaler therapy, this study could help you and your doctor better manage your condition and prevent future flare-ups.
Hear when a new Chronic Obstructive Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.